Free Trial

Lantern Pharma (LTRN) SEC Filings & 10K Form

Lantern Pharma logo
$2.94 -0.14 (-4.55%)
(As of 11/20/2024 ET)

Recent Lantern Pharma SEC Filings

DateFilerForm TypeView
11/07/2024
8:09 PM
Lantern Pharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/26/2024
3:15 PM
KEYSER D JEFFREY (Reporting)
Lantern Pharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/17/2024
3:30 PM
Lantern Pharma (Issuer)
Silberstein David S. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/17/2024
3:30 PM
Bhatia Kishor G. (Reporting)
Lantern Pharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/17/2024
3:30 PM
Chandru Vijay (Reporting)
Lantern Pharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/17/2024
3:30 PM
Lantern Pharma (Issuer)
Margrave David R. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/17/2024
3:30 PM
KEYSER D JEFFREY (Reporting)
Lantern Pharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/17/2024
3:30 PM
Lantern Pharma (Issuer)
Maccecchini Maria-Luisa (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/17/2024
3:30 PM
Lantern Pharma (Issuer)
SHARMA PANNA (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2024
11:16 PM
Lantern Pharma (Filer)
Form EFFECT
05/24/2024
3:06 PM
Lantern Pharma (Filer)
Form S-3
Registration statement under Securities Act of 1933  
05/24/2024
3:08 PM
Lantern Pharma (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
05/03/2024
6:30 AM
Lantern Pharma (Filer)
Form ARS
04/29/2024
6:30 AM
Lantern Pharma (Filer)
Form DEF 14A
04/26/2024
8:36 PM
BIOS Fund I, LP (Reporting)
Lantern Pharma (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/26/2024
8:38 PM
BIOS Fund I QP, LP (Reporting)
Lantern Pharma (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/26/2024
8:39 PM
BIOS Fund II, LP (Reporting)
Lantern Pharma (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/26/2024
8:40 PM
BIOS Fund II QP, LP (Reporting)
Lantern Pharma (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/26/2024
8:41 PM
BIOS Fund II NT, LP (Reporting)
Lantern Pharma (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/29/2024
8:54 PM
BP Directors, LP (Reporting)
Cavu Advisors, LLC (Reporting)
Cavu Management, LP (Reporting)
Kreis Leslie W. (Reporting)
Lantern Pharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/29/2024
8:54 PM
BIOS Advisors GP, LLC (Reporting)
BIOS Capital Management, LP (Reporting)
Bios Equity Partners II, LP (Reporting)
Bios Equity Partners, LP (Reporting)
BIOS Fund I QP, LP (Reporting)
BIOS Fund I, LP (Reporting)
BIOS Fund II NT, LP (Reporting)
BIOS Fund II QP, LP (Reporting)
BIOS Fund II, LP (Reporting)
Fletcher Aaron G.L. (Reporting)
Lantern Pharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/28/2024
8:40 PM
BIOS Fund II, LP (Reporting)
Lantern Pharma (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/28/2024
8:41 PM
BIOS Fund II NT, LP (Reporting)
Lantern Pharma (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/28/2024
8:41 PM
BIOS Fund II QP, LP (Reporting)
Lantern Pharma (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/19/2024
3:30 PM
BP Directors, LP (Reporting)
Cavu Advisors, LLC (Reporting)
Cavu Management, LP (Reporting)
Kreis Leslie W. (Reporting)
Lantern Pharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/19/2024
3:31 PM
BIOS Advisors GP, LLC (Reporting)
BIOS Capital Management, LP (Reporting)
Bios Equity Partners II, LP (Reporting)
Bios Equity Partners, LP (Reporting)
BIOS Fund I QP, LP (Reporting)
BIOS Fund I, LP (Reporting)
BIOS Fund II NT, LP (Reporting)
BIOS Fund II QP, LP (Reporting)
BIOS Fund II, LP (Reporting)
Fletcher Aaron G.L. (Reporting)
Lantern Pharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2023
5:00 AM
BP Directors, LP (Reporting)
Cavu Advisors, LLC (Reporting)
Cavu Management, LP (Reporting)
Kreis Leslie W. (Reporting)
Lantern Pharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2023
5:01 AM
BIOS Advisors GP, LLC (Reporting)
BIOS Capital Management, LP (Reporting)
Bios Equity Partners II, LP (Reporting)
Bios Equity Partners, LP (Reporting)
BIOS Fund I QP, LP (Reporting)
BIOS Fund I, LP (Reporting)
BIOS Fund II NT, LP (Reporting)
BIOS Fund II QP, LP (Reporting)
BIOS Fund II, LP (Reporting)
Fletcher Aaron G.L. (Reporting)
Lantern Pharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2023
5:02 AM
Bios Equity Partners, LP (Filed by)
Lantern Pharma (Subject)
Form SC 13D/A
11/24/2023
3:05 PM
Lantern Pharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:LTRN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners